Mirum Pharmaceuticals Q1 2024 GAAP EPS $(0.54) Misses $(0.48) Estimate, Sales $69.222M Miss $70.171M Estimate
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals (NASDAQ:MIRM) reported Q1 2024 earnings with a GAAP EPS of $(0.54), missing the $(0.48) estimate, and sales of $69.222M, below the $70.171M estimate. Despite the miss, both losses per share and sales showed significant improvement from the previous year.
May 08, 2024 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mirum Pharmaceuticals reported a miss on both EPS and sales estimates for Q1 2024 but showed significant year-over-year improvement.
Missing both EPS and sales estimates typically has a negative short-term impact on stock prices. However, the significant year-over-year growth in both metrics may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100